Date
Title
Date
11/02/23
Title
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
Date
10/19/23
Title
Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer
Date
09/11/23
Title
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
Date
09/05/23
Title
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Date
08/03/23
Title
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Date
07/18/23
Title
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Date
07/12/23
Title
Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares